SEC Form 4 · accession 0000899866-17-000010
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard Bell
Director
Period of report
Jan 10, 2017
Accepted (ET)
Jan 13, 2017 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Jan 10, 2017 | M | 100 | $22.90 | A | 403,719 | D | |
| Common Stock, par value $.0001 per shareF1,F2 | Jan 10, 2017 | S | 100 | $144.99 | D | 403,619 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $22.90 | Jan 10, 2017 | S | 100 | D | Apr 28, 2010 | Jan 28, 2020 | Common Stock, par value $.0001 per share | 100 | 76,838 | D |
Explanation of responses
- F1The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- F2This transaction was executed in multiple trades through a broker-dealer at prices ranging from $144.99 - $145.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.